OrthoLogic
This article was originally published in The Gray Sheet
Executive Summary
Firm no longer co-markets Hyalgan osteoarthritis treatment, as was reported in "The Gray Sheet" (July 9, 2001, p. 9); the arrangement expired at the end of 2000 (1"The Gray Sheet" Feb. 5, 2001, p. 4)
You may also be interested in...
Smith & Nephew's Supartz Is Third Player In HA Osteoarthritis Market
Smith & Nephew's 400-rep sales force plans to emphasize the extensive clinical experience behind the firm's Supartz hyaluronic acid-based injectable treatment for osteoarthritis of the knee in marketing the product to orthopedic surgeons.
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.